Towards Healthcare
Monoclonal Antibody for Asthma and COPD Market Drives US$ 58.94 Billion by 2035

Monoclonal Antibody for Asthma and COPD Market Gains AI Integration Edge

According to market projections, the monoclonal antibody for asthma and COPD sector is expected to grow from USD 34.02 billion in 2025 to USD 58.94 billion by 2035, reflecting a CAGR of 5.65%, providing detailed analysis of disease-specific segments, regional distribution (NA, EU, APAC, LA, MEA), manufacturer data, competitive benchmarking, value chain stages, and trade statistics, driven by rising chronic respiratory disease prevalence and adoption of novel mAbs.

Content

  • Last Updated: 25 November 2025
  • Report Covered: [Revenue + Volume]
  • Historical Year: 2021-2023
  • Base Year: 2024
  • Estimated Years: 2025-2034

About The Author

Shivani Zoting is a dedicated research analyst specializing in the healthcare industry. With a strong academic foundation, a B.Sc. in Biotechnology and an MBA in Pharmabiotechnology, she brings a unique blend of scientific understanding and market strategy to her research.

Shivani contributes to Towards Healthcare and plays an active role at Precedence Research, where she focuses on delivering in-depth market intelligence, competitive analysis, and trend forecasting across pharmaceuticals, medical devices, digital health, and healthcare services. Her insights support healthcare companies, investors, and policymakers in making data-backed decisions in a highly regulated and rapidly evolving sector.

Additionally, Shivani collaborates with Statifacts, further expanding her healthcare domain reach by engaging in diverse projects across global markets. Her strength lies in transforming complex clinical and commercial data into strategic narratives that help stakeholders navigate the future of healthcare.

Talk to us
FAQ's

The monoclonal antibody for asthma and COPD market stands at USD 35.94 billion in 2026 and is expected to reach USD 58.94 billion by 2035, growing at a CAGR of 5.65% from 2026 to 2035.

North America is currently leading the monoclonal antibody for asthma and COPD market share 45% due to the increasing prevalence of asthma and COPD for different reasons.

Some key players include AstraZeneca plc, GlaxoSmithKline plc, Sanofi S.A., Regeneron Pharmaceuticals, Inc., and Novartis AG.

IgE antibodies are responsible for asthma.

WHO, NIH, USFDA, CDC, ClinicalTrials.gov, PubMed, NEJM, NIAID, GINA, NAC.
Any Questions